Inactivation of fibroblast growth factor binding protein 3 causes anxiety-related behaviors

Molecular and Cellular Neuroscience

Volumn 46, Issue 1, 2011, Pages 200-212

  Yamanaka, Yasunari ^a,g   Kitano, Ayumi ^a   Takao, Keizo ^a,b,c   Prasansuklab, Anchalee ^d   Mushiroda, Taisei ^d   Yamazaki, Keiko ^d   Kumada, Tomohiro ^a   Shibata, Minoru ^a   Takaoka, Yuki ^a   Awaya, Tomonari ^a   Kato, Takeo ^a   Abe, Takaya ^e   Iwata, Nakao ^b   Miyakawa, Tsuyoshi ^a,b,c   Nakamura, Yusuke ^d,f   Nakahata, Tatsutoshi ^a   Heike, Toshio ^a  

^a KYOTO UNIVERSITY   (Japan)

^b FUJITA HEALTH UNIVERSITY   (Japan)

^c JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^d RIKEN   (Japan)

^e RIKEN Center for Biosystems Dynamics Research   (Japan)

^f UNIVERSITY OF TOKYO   (Japan)

^g SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Animal models; Anxiety; Extracellular signal regulated kinase (ERK); FGF binding protein 3 (FGF BP3); Fibroblast growth factor (FGF); Orbitofrontal cortex

Indexed keywords

BETA GALACTOSIDASE; BINDING PROTEIN; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR BINDING PROTEIN 3; MITOGEN ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANXIETY; ARTICLE; AVERSIVE BEHAVIOR; BRAIN NERVE CELL; CONTROLLED STUDY; EMOTION; ENZYME ACTIVATION; FEEDING BEHAVIOR; FEMALE; GENE DELETION; HUMAN; HUMAN CELL; HYPOPHAGIA; LATENT PERIOD; LIGHT DARK CYCLE; MALE; MOUSE; NONHUMAN; OPEN FIELD BEHAVIOR; ORBITAL CORTEX; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PROTEIN INTERACTION;

ANIMALS; ANXIETY; BEHAVIOR, ANIMAL; CARRIER PROTEINS; CELL LINE; CEREBRAL CORTEX; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FIBROBLAST GROWTH FACTOR 2; HUMANS; MALE; MAP KINASE SIGNALING SYSTEM; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEUROPSYCHOLOGICAL TESTS;

ANIMALIA; MUS;

EID: 78650865658     PISSN: 10447431     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mcn.2010.09.003     Document Type: Article

References (70)

1. Abuharbeid S., Czubayko F., Aigner A. The fibroblast growth factor-binding protein FGF-BP. Int. J. Biochem. Cell Biol. 2006, 38:1463-1468.
2. Aigner A., Malerczyk C., Houghtling R., Wellstein A. Tissue distribution and retinoid-mediated downregulation of an FGF-binding protein (FGF-BP) in the rat. Growth Factors 2000, 18:51-62.
3. Aigner A., Butscheid M., Kunkel P., Krause E., Lamszus K., Wellstein A., Czubayko F. An FGF-binding protein (FGF-BP) exerts its biological function by parallel paracrine stimulation of tumor cell and endothelial cell proliferation through FGF-2 release. Int. J. Cancer 2001, 92:510-517.
4. Aigner A., Ray P.E., Czubayko F., Wellstein A. Immunolocalization of an FGF-binding protein reveals a widespread expression pattern during different stages of mouse embryo development. Histochem. Cell Biol. 2002, 117:1-11.
5. Ailing F., Fan L., Li S., Manji S. Role of extracellular signal-regulated kinase signal transduction pathway in anxiety. J. Psychiatr. Res. 2008, 43:55-63.
6. Ansorge M.S., Zhou M., Lira A., Hen R., Gingrich J.A. Early-life blockade of the 5-HT transporter alters emotional behavior in adult mice. Science 2004, 306:879-881.
7. Bachis A., Mallei A., Cruz M.I., Wellstein A., Mocchetti I. Chronic antidepressant treatments increase basic fibroblast growth factor and fibroblast growth factor-binding protein in neurons. Neuropharmacology 2008, 55:1114-1120.
8. Bale T.L., Contarino A., Smith G.W., Chan R., Gold L.H., Sawchenko P.E., Koob G.F., Vale W.W., Lee K.F. Mice deficient for corticotropin-releasing hormone receptor-2 display anxiety-like behaviour and are hypersensitive to stress. Nat. Genet. 2000, 24:410-414.
9. Barbas H., Saha S., Rempel-Clower N., Ghashghaei T. Serial pathways from primate prefrontal cortex to autonomic areas may influence emotional expression. BMC Neurosci. 2003, 4:25-36.
10. Beer H.D., Bittner M., Niklaus G., Munding C., Max N., Goppelt A., Werner S. The fibroblast growth factor binding protein is a novel interaction partner of FGF-7, FGF-10 and FGF-22 and regulates FGF activity: implications for epithelial repair. Oncogene 2005, 24:5269-5277.
11. Bishop S.J. Neurocognitive mechanisms of anxiety: an integrative account. Trends Cogn. Sci. 2007, 11:307-316.
12. Burmeister M., McInnis M.G., Zöllner S. Psychiatric genetics: progress amid controversy. Nat. Rev. Genet. 2008, 9:527-540.
13. Canli T., Lesch K.P. Long story short: the serotonin transporter in emotion regulation and social cognition. Nat. Neurosci. 2007, 10:1103-1109.
14. Cao L., Jiao X., Zuzga D.S., Liu Y., Fong D.M., Young D., During M.J. VEGF links hippocampal activity with neurogenesis, learning and memory. Nat. Genet. 2004, 36:827-835.
15. Crawley J.N. Behavioral phenotyping strategies for mutant mice. Neuron 2008, 57:809-818.
16. Cryan J.F., Holmes A. The ascent of mouse: advances in modelling human depression and anxiety. Nat. Rev. Drug Discov. 2005, 4:775-790.
17. Czubayko F., Smith R.V., Chung H.C., Wellstein A. Tumor growth and angiogenesis induced by a secreted binding protein for fibroblast growth factors. J. Biol. Chem. 1994, 269:28243-28248.
18. Czubayko F., Liaudet-Coopman E.D., Aigner A., Tuveson A.T., Berchem G.J., Wellstein A. A secreted FGF-binding protein can serve as the angiogenic switch in human cancer. Nat. Med. 1997, 3:1137-1140.
19. Dulawa S.C., Hen R. Recent advances in animal models of chronic antidepressant effects: the novelty-induced hypophagia test. Neurosci. Biobehav. Rev. 2005, 29:771-783.
20. Dwivedi Y., Rizavi H.S., Roberts R.C., Conley R.C., Tamminga C.A., Pandey G.N. Reduced activation and expression of ERK1/2 MAP kinase in the post-mortem brain of depressed suicide subjects. J. Neurochem. 2001, 77:916-928.
21. Dwivedi Y., Rizavi H.S., Conley R.R., Pandey G.N. ERK MAP kinase signaling in post-mortem brain of suicide subjects: differential regulation of upstream Raf kinases Raf-1 and B-Raf. Mol. Psychiatry 2006, 11:86-98.
22. Evans S.J., Choudary P.V., Neal C.R., Li J.Z., Vawter M.P., Tomita H., Lopez J.F., Thompson R.C., Meng F., Stead J.D., Walsh D.M., Myers R.M., Bunney W.E., Watson S.J., Jones E.G., Akil H. Dysregulation of the fibroblast growth factor system in major depression. Proc. Natl. Acad. Sci. USA 2004, 101:15506-15511.
23. Flajolet M., Wang Z., Futter M., Shen W., Nuangchamnong N., Bendor J., Wallach I., Nairn A.C., Surmeier D.J., Greengard P. FGF acts as a co-transmitter through adenosine A(2A) receptor to regulate synaptic plasticity. Nat. Neurosci. 2008, 11:1402-1409.
24. Floyd N.S., Price J.L., Ferry A.T., Keay K.A., Bandler R. Orbitomedial prefrontal cortical projections to hypothalamus in the rat. J. Comp. Neurol. 2001, 432:307-328.
25. Forget C., Stewart J., Trudeau L.E. Impact of basic FGF expression in astrocytes on dopamine neuron synaptic function and development. Eur. J. Neurosci. 2006, 23:608-616.
26. Fox A.S., Shelton S.E., Oakes T.R., Converse A.K., Davidson R.J., Kalin N.H. Orbitofrontal cortex lesions alter anxiety-related activity in the primate bed nucleus of stria terminalis. J. Neurosci. 2010, 30:7023-7027.
27. Gaughran F., Payne J., Sedgwick P.M., Cotter D., Berry M. Hippocampal FGF-2 and FGFR1 mRNA expression in major depression, schizophrenia and bipolar disorder. Brain Res. Bull. 2006, 70:221-227.
28. Gordon J.A., Hen R. Genetic approaches to the study of anxiety. Annu. Rev. Neurosci. 2004, 27:193-222.
29. Grachev I.D., Apkarian A.V. Anxiety in healthy humans is associated with orbital frontal chemistry. Mol. Psychiatry 2000, 5:482-488.
30. Gross C., Hen R. The developmental origins of anxiety. Nat. Rev. Neurosci. 2004, 5:545-552.
31. Hashimoto R., Numakawa T., Ohnishi T., Kumamaru E., Yagasaki Y., Ishimoto T., Mori T., Nemoto K., Adachi N., Izumi A., Chiba S., Noguchi H., Suzuki T., Iwata N., Ozaki N., Taguchi T., Kamiya A., Kosuga A., Tatsumi M., Kamijima K., Weinberger D.R., Sawa A., Kunugi H. Impact of the DISC1 Ser704Cys polymorphism on risk for major depression, brain morphology and ERK signaling. Hum. Mol. Genet. 2006, 15:3024-3033.
32. Herrman H., Chopra P. Quality of life and neurotic disorders in general healthcare. Curr. Opin. Psychiatry 2009, 22:61-68.
33. Hettema J.M., Neale M.C., Kendler K.S. A review and meta-analysis of the genetic epidemiology of anxiety disorders. Am. J. Psychiatry 2001, 158:1568-1578.
34. Hunter A.J., Nolan P.M., Brown S.D. Towards new models of disease and physiology in the neurosciences: the role of induced and naturally occurring mutations. Hum. Mol. Genet. 2000, 9:893-900.
35. Kringelbach M.L. The human orbitofrontal cortex: linking reward to hedonic experience. Nat. Rev. Neurosci. 2005, 6:691-702.
36. Kumada T., Yamanaka Y., Kitano A., Shibata M., Awaya T., Kato T., Okawa K., Abe T., Oshima N., Nakahata T., Heike T. Ttyh1, a Ca-binding protein localized to the endoplasmic reticulum, is required for early embryonic development. Dev. Dyn. 2010, 239:2233-2245.
37. Kurtz A., Wang H.L., Darwiche N., Harris V., Wellstein A. Expression of a binding protein for FGF is associated with epithelial development and skin carcinogenesis. Oncogene 1997, 14:2671-2681.
38. Maragnoli M.E., Fumagalli F., Gennarelli M., Racagni G., Riva M.A. Fluoxetine and olanzapine have synergistic effects in the modulation of fibroblast growth factor 2 expression within the rat brain. Biol. Psychiatry 2004, 55:1095-1102.
39. Martinowich K., Manji H., Lu B. New insights into BDNF function in depression and anxiety. Nat. Neurosci. 2007, 10:1089-1093.
40. Meshi D., Drew M.R., Saxe M., Ansorge M.S., David D., Santarelli L., Malapani C., Moore H., Hen R. Hippocampal neurogenesis is not required for behavioral effects of environmental enrichment. Nat. Neurosci. 2006, 9:729-731.
41. Miyakawa T., Yamada M., Duttaroy A., Wess J. Hyperactivity and intact hippocampus-dependent learning in mice lacking the M1 muscarinic acetylcholine receptor. J. Neurosci. 2001, 21:5239-5250.
42. Nakajima R., Takao K., Huang S.M., Takano J., Iwata N., Miyakawa T., Saido T.C. Comprehensive behavioral phenotyping of calpastatin-knockout mice. Mol. Brain 2008, 1:7.
43. Qi X., Lin W., Li J., Pan Y., Wang W. The depressive-like behaviors are correlated with decreased phosphorylation of mitogen-activated protein kinases in rat brain following chronic forced swim stress. Behav. Brain Res. 2006, 175:233-240.
44. Qi X., Lin W., Li J., Li H., Wang W., Wang D., Sun M. Fluoxetine increases the activity of the ERK-CREB signal system and alleviates the depressive-like behavior in rats exposed to chronic forced swim stress. Neurobiol. Dis. 2008, 31:278-285.
45. Raballo R., Rhee J., Lyn-Cook R., Leckman J.F., Schwartz M.L., Vaccarino F.M. Basic fibroblast growth factor (Fgf2) is necessary for cell proliferation and neurogenesis in the developing cerebral cortex. J. Neurosci. 2000, 20:5012-5023.
46. Ray R., Cabal-Manzano R., Moser A.R., Waldman T., Zipper L.M., Aigner A., Byers S.W., Riegel A.T., Wellstein A. Up-regulation of fibroblast growth factor-binding protein, by beta-catenin during colon carcinogenesis. Cancer Res. 2003, 63:8085-8089.
47. Rempel-Clower N.L. Role of orbitofrontal cortex connections in emotion. Ann. NY Acad. Sci. 2007, 1121:72-86.
48. Roberts A.C. Primate orbitofrontal cortex and adaptive behaviour. Trends Cogn. Sci. 2006, 10:83-90.
49. Rudebeck P.H., Walton M.E., Millette B.H., Shirley E., Rushworth M.F., Bannerman D.M. Distinct contributions of frontal areas to emotion and social behaviour in the rat. Eur. J. Neurosci. 2007, 26:2315-2326.
50. Ryu J., Futai K., Feliu M., Weinberg R., Sheng M. Constitutively active Rap2 transgenic mice display fewer dendritic spines, reduced extracellular signal-regulated kinase signaling, enhanced long-term depression, and impaired spatial learning and fear extinction. J. Neurosci. 2008, 28:8178-8188.
51. Saddoris M.P., Gallagher M., Schoenbaum G. Rapid associative encoding in basolateral amygdala depends on connections with orbitofrontal cortex. Neuron 2005, 46:321-331.
52. Schoenbaum G., Roesch M. Orbitofrontal cortex, associative learning, and expectancies. Neuron 2005, 47:633-636.
53. Schramm N.L., McDonald M.P., Limbird L.E. The α(2a)-adrenergic receptor plays a protective role in mouse behavioral models of depression and anxiety. J. Neurosci. 2001, 21:4875-4882.
54. Shirasaki R., Lewcock J.W., Lettieri K., Pfaff S.L. FGF as a target-derived chemoattractant for developing motor axons genetically programmed by the LIM code. Neuron 2006, 50:841-853.
55. Smith K.M., Ohkubo Y., Maragnoli M.E., Rasin M.R., Schwartz M.L., Sestan N., Vaccarino F.M. Midline radial glia translocation and corpus callosum formation require FGF signaling. Nat. Neurosci. 2006, 9:787-797.
56. Sun H., Green T.A., Theobald D.E., Birnbaum S.G., Graham D.L., Zeeb F.D., Nestler E.J., Winstanley C.A. Yohimbine increases impulsivity through activation of cAMP response element binding in the orbitofrontal cortex. Biol. Psychiatry 2010, 67:649-656.
57. Takao K., Miyakawa T. Light/dark transition test for mice. J. Vis. Exp. 2006, 1:104-105.
58. Tassi E., Al-Attar A., Aigner A., Swift M.R., McDonnell K., Karavanov A., Wellstein A. Enhancement of fibroblast growth factor (FGF) activity by an FGF-binding protein. J. Biol. Chem. 2001, 276:40247-40253.
59. Tassi E., Walter S., Aigner A., Cabal-Manzano R.H., Ray R., Reier P.J., Wellstein A. Effects on neurite outgrowth and cell survival of a secreted fibroblast growth factor binding protein upregulated during spinal cord injury. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2007, 293:R775-R783.
60. Turner C.A., Akil H., Watson S.J., Evans S.J. The fibroblast growth factor system and mood disorders. Biol. Psychiatry 2006, 59:1128-1135.
61. Turner C.A., Calvo N., Frost D.O., Akil H., Watson S.J. The fibroblast growth factor system is downregulated following social defeat. Neurosci. Lett. 2008, 430:147-150.
62. Umemori H., Linhoff M.W., Ornitz D.M., Sanes J.R. FGF22 and its close relatives are presynaptic organizing molecules in the mammalian brain. Cell 2004, 118:257-270.
63. Vaccarino F.M., Schwartz M.L., Raballo R., Nilsen J., Rhee J., Zhou M., Doetschman T., Coffin J.D., Wyland J.J., Hung Y.T. Changes in cerebral cortex size are governed by fibroblast growth factor during embryogenesis. Nat. Neurosci. 1999, 2:246-253.
64. Wei Q., Lu X.Y., Liu L., Schafer G., Shieh K.R., Burke S., Robinson T.E., Watson S.J., Seasholtz A.F., Akil H. Glucocorticoid receptor overexpression in forebrain: a mouse model of increased emotional lability. Proc. Natl. Acad. Sci. USA 2004, 101:11851-11856.
65. Wu D.Q., Kan M.K., Sato G.H., Okamoto T., Sato J.D. Characterization and molecular cloning of a putative binding protein for heparin-binding growth factors. J. Biol. Chem. 1991, 266:16778-16785.
66. Xie B., Tassi E., Swift M.R., McDonnell K., Bowden E.T., Wang S., Ueda Y., Tomita Y., Riegel A.T., Wellstein A. Identification of the fibroblast growth factor (FGF)-interacting domain in a secreted FGF-binding protein by phage display. J. Biol. Chem. 2006, 281:1137-1144.
67. Yamanaka Y., Heike T., Kumada T., Shibata M., Takaoka Y., Kitano A., Shiraishi K., Kato T., Nagato M., Okawa K., Furushima K., Nakao K., Nakamura Y., Taketo M.M., Aizawa S., Nakahata T. Loss of Borealin/DasraB leads to defective cell proliferation, p53 accumulation and early embryonic lethality. Mech. Dev. 2008, 125:441-450.
68. Yamasaki N., Maekawa M., Kobayashi K., Kajii Y., Maeda J., Soma M., Takao K., Tanda K., Ohira K., Toyama K., Kanzaki K., Fukunaga K., Sudo Y., Ichinose H., Ikeda M., Iwata N., Ozaki N., Suzuki H., Higuchi M., Suhara T., Yuasa S., Miyakawa T. Alpha-CaMKII deficiency causes immature dentate gyrus, a novel candidate endophenotype of psychiatric disorders. Mol. Brain 2008, 1:6.
69. Zhang W., Chen Y., Swift M.R., Tassi E., Stylianou D.C., Gibby K.A., Riegel A.T., Wellstein A. Effect of FGF-binding protein 3 on vascular permeability. J. Biol. Chem. 2008, 283:28329-28337.
70. Zimmerman M., Chelminski I., McDermut W. Major depressive disorder and axis I diagnostic comorbidity. J. Clin. Psychiatry 2002, 63:187-193.